Iodine-123-N-ω-fluoropropyl-2/β-carbomethoxy3β-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease

Journal of Nuclear Medicine

Volumn 39, Issue 7, 1998, Pages 1143-1148

  Tissingh, Gerrit ^a   Booij, Jan ^b   Bergmans, Paul ^b   Winogrodzka, Ania ^b   Janssen, Anton G M ^b   Van Royen, Eric A ^b   Stoof, Johannes C ^b   Wolters, Erik Ch ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Cocaine analogs; Dopamine transporter imaging; Parkinson's disease; SPECT

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE TRANSPORTER; IODINE 123; POTASSIUM IODIDE;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORPUS STRIATUM; DISCRIMINANT ANALYSIS; DISEASE SEVERITY; DRUG BINDING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; AGING; CARRIER PROTEINS; CASE-CONTROL STUDIES; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0031816315     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973;20: 415-455.
2. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991;9:43-49.
3. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
4. 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 1988;77:192-201.
5. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431.
6. 11C]β-CFT in early Parkinson's disease. Synapse 1995;21:97-103.
7. 123i]β-CIT. Binding kinetics in the human brain. J Neural Transm 1993;94:137-146.
8. Innis RB, Seibyl JB, Scanley BE, et al. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
9. 123I]β-CIT SPECT. Parkinsonism Relat Disord 1995;1:47-51.
10. 123I}β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
11. 123I]β-CIT binding with SPECT in controls, early and late Parkinson's disease. Nucl Med Biol 1995;22:985-991.
12. 123I]β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
13. Asenbaum S, Brücke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6.
14. 123I]β-CIT in vivo binding to dopamine transporters in healthy subjects. J Cereb Blood Flow Melab 1994;14:982-994.
15. Neumeyer JL, Wang S, Gao Y, et al. N-ω-Fluoroalkyl analogs of (1R)-2β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission CT imaging of dopamine transporters. J Med Chem 1994;37:1558-1561.
16. 123I]N-ω-fluoroalkyl-2β-carboxy-3β-(4-iodophenyl) nortropane esters in baboons. Nucl Med Biol 1995;22:211-219.
17. Neumeyer JL, Tamagnan G, Wang S, et al. N-substituted analogs of 2β-carbomethoxy-3β-(4′-iodophenyl)tropane (β-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. J Med Chem 1996;39:543-548.
18. 11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolic studies, and positron emission tomography examinations. Nucl Med Biol 1995;22:905-913.
19. 18F]N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol 1996;23:999-1004.
20. Kuikka JT, Bergström KA, Ahonen A, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356-360.
21. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 1996;37:1129-1133.
22. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71.
23. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140.
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
25. Fahn S, Elton R. Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstern M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-164.
26. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
27. Hughes A, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in Parkinsonian syndromes. Lancet 1990;336:32-34.
28. 3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol 1993;250:261-266.
29. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
30. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-1765.
31. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;876:876-880.
32. Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989;26: 766-770.
33. Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
34. Van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181.
35. Volkow ND, Ding Y-S, Fowler JS, et al. Dopamine transporters decrease with age. J Nucl Med 1996;37:554-559.
36. Tissingh G, Bergmans P, Booij J, et al. Nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP/SPECT and fluorine-18-FDOPA/PET [Letter]. J Nucl Med 1997; 37:1271-1272.
37. 123I]β-CIT SPECT. J Neurol 1998;245:14-20.
38. Seibyl J, Marek K, Sheff K, Neumeyer J, Innis R. Comparison of [I-123]FP-CIT and [I-123]β-CIT for SPECT imaging of dopamine transporters in Parkinson's disease [Abstract]. J Nucl Med 1996;37(suppl): 133.